New Indication for Xpovio®

June 26, 2020

New Indication for Xpovio®

Onco360® has been selected by Karyopharm to be a specialty pharmacy partner for XPOVIO® (selinexor), a new oral treatment for adult patients with relapsed or refractory diffused large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

“Onco360 is excited to be selected as a specialty pharmacy provider for XPOVIO patients,” said Paul Jardina, President and CEO, Onco360. “The recent approval of XPOVIO unlocks a new treatment option for relapsed or refractory DLBCL patients who have failed previous lines of treatment. As a provider of this key treatment, Onco360 can support the highly specialized needs of relapsed or refractory DLBCL patients and their physicians across the states.”

DLBCL is the most common type of non-Hodgkin lymphoma (NHL). According to the National Comprehensive Cancer Network Guidelines for B-Cell Lymphomas, 74,200 patients are diagnosed with NHL annually with a corresponding 19,970 deaths from NHL annually. Approximately 32% of NHL cases are classified as DLBCL. The median age at initial diagnosis with DLBCL is 66 years old. The five-year overall survival for DLBCL is 63.8% when considering all stages of disease.

XPOVIO is manufactured by Karyopharm Therapeutics, a global, commercial-stage, research-based biotechnology company, and was previously approved by the U.S. FDA for the treatment of adult patients with relapsed or refractory multiple myeloma, in combination with dexamethasone, who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. The FDA’s approval of XPOVIO for relapsed/refractory DLBCL is based on the results of the Phase IIb SADAL (NCT02227251) Clinical Trial which demonstrated a 29% overall response rate in patients who failed two to five prior lines of systemic therapy.

Referral forms and information on how to order are available at Onco360.com/Order. For full prescribing information, visit XPOVIO.com.